In the Journal of Antimicrobial Chemotherapy Stein Schalkwijk, Rob ter Heine, Angela Colbers and David Burger investigated how pregnant women should be treated with the anti-HIV drug darunavir.Darunavir is pharmacotherapeutic cornerstone in treatment of HIV. During pregnancy subtherapeutic exposure may occur, leaving a whole new generation at risk for infection with HIV and transmission of drug resistance. Therefore, it was investigated what dosing regimen was most likely to result in therapeutic exposure. It was found that a twice-daily dose of 600 mg, in combination with ritonavir (100 mg) was the best dose during pregnancy.
Evaluating darunavir/ritonavir dosing regimens for HIV-positive pregnant women using semi-mechanistic pharmacokinetic modelling.
Schalkwijk S, Ter Heine R, Colbers A, Capparelli E, Best BM, Cressey TR, Greupink R, Russel FGM, Moltó J, Mirochnick M, Karlsson MO, Burger DM.
Stein Schalkwijk, Rob ter Heine, Angela Colbers and David Burger are all members of theme Infectious diseases and global health.
Related news items
Bart Kiemeney will step down as director RIHS Invitation21 March 2019
We would like to give you the opportunity to say goodbye to Bart as director of the Radboud Institute for Health Sciences on 28 March 16.00 hrs in the Tuinzaal.read more
Protein supplementation improves lean body mass in physically active older adults21 March 2019
In the Journal of Cachexia, Sarcopenia & Muscle, Dominique ten Haaf and colleagues described a randomized clinical trial to assess the effects of 12-weeks protein supplementation on body characteristics.read more
eHealth Apps Replacing or Complementing Health Care Contacts21 March 2019
In the Journal of Medical Internet Research, Pim Assendelft and colleagues from the University of Applied sciences Arnhem Nijmegen showed that still relatively little is known about the adverse effects of health apps when used to replace or complement contacts with doctors or nurses.read more